Article Sidebar

PDF
Date Published: 24/10/2021
Abstract Views: 227
Views PDF: 148
DOI: https://doi.org/10.51298/vmj.v506i2.1293
Issue
Vol. 506 No. 2 (2021)
Section
Các bài báo
How to Cite
Thị Thúy, N. ., & Việt Thắng, L. . (2021). SURVEYING ON LEVEL OF PLASMA ASYMETRIC DIMETHYLARGININE IN END-STAGE RENAL DISEASE PATIENTS. Vietnam Medical Journal, 506(2). https://doi.org/10.51298/vmj.v506i2.1293

SURVEYING ON LEVEL OF PLASMA ASYMETRIC DIMETHYLARGININE IN END-STAGE RENAL DISEASE PATIENTS

Nguyễn Thị Thúy1,, Lê Việt Thắng2
1 108 Military Central Hospital
2 Military Hospital 103, Vietnam Military Medical University

Main Article Content

Abstract

Objectives: Surveying on plasma asymmetric dimethylarginine in end-stage renal disease patients who were indicated kidney transplantation and association with cardiovascular risk factors. Subjects and Methods: A controlled cross-sectional study in 118 end-stage renal disease (ESRD) patients who have indication kidney transplantation and 83 controlled healthy people at 103 Military hospital from March/2018 to April/2020. Results: The median concentration of plasma ADMA in the patient group: 0.61 µmol/l was higher than the control group: 0.32 µmol/l with p < 0.001. There were 75.4% of patients increased plasma ADMA. There were correlation between ADMA level and dislipidemia (OR= 6.19), overweight or obesity (OR = 4.71), smoke (OR = 3.58). Conclusion: Elevated plasma ADMA concentrations are common and associated with some cardiovascular risk factors in ESRD patients.

Article Details

Keywords

Asymetric dimethylarginin (ADMA), End stage renal disease (ESRD), Kidney transplantation, cardiovascular risk factor

References

1. G. B. D. Chronic Kidney Disease Collaboration (2020), "Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017", Lancet, 395(10225), tr. 709-733.
2. C. L. Gopu, P. R. Hari, R. George và các cộng sự. (2013), "Simultaneous determination of homocysteine and asymmetric dimethylarginine in human urine by liquid chromatography-tandem mass spectrometry", J Chromatogr B Analyt Technol Biomed Life Sci, 939, tr. 32-7.
3. X. Liu, X. Xu, R. Shang và các cộng sự. (2018), "Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease", Nitric Oxide, 78, tr. 113-120.
4. A. D. Dobrian (2012), "ADMA and NOS regulation in chronic renal disease: beyond the old rivalry for l-arginine", Kidney Int, 81(8), tr. 722-4.
5. Võ Tam Hoàng Trọng Ái Quốc, Hoàng Viết Thắng (2015), "Nghiên cứu nồng độ Asymetric Dimethylarginine huyết tương và mối liên quan với một số yếu tố nguy cơ tim mạch ở bệnh nhân bệnh thận mạn giai đoạn cuối", Tạp chí Y dược học- Trường Đại học Y dược Huế, Tập 6 (02) - Số 32/2016; Trang: 51.
6. Nguyễn Thị Thúy Hằng Nguyễn Hữu Thịnh, Hoàng Bùi Bảo (2014), "Khảo sát một số yếu tố nguy cơ tim mạch và bất thường điện tim, siêu âm tim ở bệnh nhân đang chờ ghép thận", Tại chí y dược học.
7. M. Y. Said, R. M. Douwes, M. van Londen và các cộng sự. (2019), "Effect of renal function on homeostasis of asymmetric dimethylarginine (ADMA): studies in donors and recipients of renal transplants", Amino Acids, 51(3), tr. 565-575.
8. J. Eiselt, D. Rajdl, J. Racek và các cộng sự. (2014), "Asymmetric dimethylarginine and progression of chronic kidney disease: a one-year follow-up study", Kidney Blood Press Res, 39(1), tr. 50-7.
9. T. M. Lu, M. Y. Chung, C. C. Lin và các cộng sự. (2011), "Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease", Clin J Am Soc Nephrol, 6(7), tr. 1566-72.